Pleiotrophin drives a prometastatic immune niche in breast cancer

Metastatic cancer cells adapt to thrive in secondary organs. To investigate metastatic adaptation, we performed transcriptomic analysis of metastatic and non-metastatic murine breast cancer cells. We found that pleiotrophin (PTN), a neurotrophic cytokine, is a metastasis-associated factor that is expressed highly by aggressive breast cancers. Moreover, elevated PTN in plasma correlated significantly with metastasis and reduced survival of breast cancer patients. Mechanistically, we find that PTN activates NF-kappa B in cancer cells leading to altered cytokine production, subsequent neutrophil recruitment, and an immune suppressive microenvironment. Consequently, inhibition of PTN, pharmacologically or genetically, reduces the accumulation of tumor-associated neutrophils and reverts local immune suppression, resulting in increased T cell activation and attenuated metastasis. Furthermore, inhibition of PTN significantly enhanced the efficacy of immune checkpoint blockade and chemotherapy in reducing metastatic burden in mice. These findings establish PTN as a previously unrecognized driver of a prometastatic immune niche and thus represents a promising therapeutic target for the treatment of metastatic breast cancer. Metastatic cancer cells thrive in secondary organs by producing PTN and activating the NF-kappa B pathway. This leads to increased cytokine production, neutrophil recruitment, and T cell dysfunction. Targeting PTN presents a promising addition to the current regimen for treating metastatic TNBC.

Automated summary

Metastatic cancer cells adapt to secondary organs by producing PTN and activating the NF-kappa B pathway, leading to increased cytokine production, neutrophil recruitment, and T cell dysfunction. Targeting PTN presents a promising addition to the current regimen for treating metastatic TNBC.